PRAX Praxis Precision Medicines, Inc. stock chart & analysis
Conviction 41HealthcareScan · Fri, Nov 6, 2026Praxis Precision Medicines, Inc. (PRAX) closed at $277.62 (+5.72%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 51, RS Rating 93, -29.3% from its 52-week high, -5.8% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Tue, Jun 30, 2026 · quarterly.
PRAX technical analysis
Trend
PRAX is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 4.9% below the 50-day ($291.73) and 11.6% below the 200-day ($313.95). ADX(14) at 18 points to a weak trend — more range than direction. It meets 2 of 8 trend-template criteria.
Momentum
RSI(14) is 51, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 93 puts its weighted 12-month performance ahead of about 93% of the US market.
Volume and volatility
Volume on the latest session ran 0.7× its 20-day average. It trades about $124.4M a day on average. ATR(14) is $14.35, 5.2% of price — its typical daily range. Chaikin Money Flow (-0.09) shows distribution.
Key levels
The chart pattern's support is $243.82 and its resistance $297.04. The 52-week range is $159.74 to $392.70; price is 29.3% below the high and 73.8% above the low. The VWAP anchored at the 52-week high is $293.27, above price.
Performance
PRAX returned -2.9% (1 week), +5.3% (1 month), -24.4% (3 months), -15.9% (6 months), +68.6% (1 year), -5.8% (year to date).
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Pharmaceutical Preparations · Listed 2020 · 10,998 employees
Congress activity
Disclosed STOCK Act trades in PRAX · 2 recent
Insider activity
SEC Form 4 transactions in PRAX · open-market 6 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Souza Marcio Chief Executive Officer · Common Stock · 2026-07-08 | Gift | 20.52K | — | 2026-07-08 | 2026-07-08 |
Souza Marcio Chief Executive Officer · Common Stock · 2026-07-08 | Gift | 2.6K | — | 2026-07-08 | 2026-07-08 |
DeSimone Jill Director · Common Stock · 2026-06-24 | Sell | 1.24K | $382K | 2026-06-24 | 2026-06-26 |
DeSimone Jill Director · Common Stock · 2026-06-24 | Sell | 999 | $309K | 2026-06-24 | 2026-06-26 |
DeSimone Jill Director · Common Stock · 2026-06-24 | Sell | 1.75K | $544K | 2026-06-24 | 2026-06-26 |
DeSimone Jill Director · Common Stock · 2026-06-24 | Sell | 1.28K | $403K | 2026-06-24 | 2026-06-26 |
DeSimone Jill Director · Common Stock · 2026-06-24 | Exercise | 8.57K | $379K | 2026-06-24 | 2026-06-26 |
DeSimone Jill Director · Common Stock · 2026-06-24 | Exercise | 3.03K | $447K | 2026-06-24 | 2026-06-26 |
DeSimone Jill Director · Common Stock · 2026-06-24 | Sell | 10 | $3K | 2026-06-24 | 2026-06-26 |
DeSimone Jill Director · Common Stock · 2026-06-24 | Sell | 120 | $36K | 2026-06-24 | 2026-06-26 |
SEC filings
EDGAR filings in PRAX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.